ESCRT-dependent YAP degradation by AKT blockade overcomes adaptive resistance to RAS(ON) inhibition in pancreatobiliary cancer
Adaptive YAP/TAZ activation limits durable responses to RAS pathway inhibition in pancreatobiliary cancers. We identify AKT as a regulator of YAP protein stability and define a non-canonical, therapeutically actionable ESCRT-dependent lysosomal degradation pathway. Capivasertib, an FDA-approved pan-AKT inhibitor, triggered post-translational YAP degradation by 12 hours, routing YAP to ESCRT…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
